Chinese Expert Consensus for the Application of rh-aFGF for Chronic Refractory Wounds

Area of Science:

• Regenerative Medicine
• Wound Healing Biology
• Biotechnology

Background:

• Chronic refractory wounds (CRWs) significantly impair patient quality of life and pose a societal burden.
• Recombinant human acidic fibroblast growth factor (rh-aFGF) is a growth factor with established efficacy in promoting wound healing.
• Standardized clinical application guidelines are needed to optimize rh-aFGF's therapeutic potential.

Purpose of the Study:

• To develop an expert consensus for the clinical application of rh-aFGF in treating chronic refractory wounds.
• To standardize the use of rh-aFGF and enhance its clinical value.
• To provide a reference for clinicians using rh-aFGF and similar growth factor therapies.

Main Methods:

• Comprehensive literature search across major databases (PubMed, Web of Science, Medline, CNKI, Wangfang).
• Expert recommendations formulated through assessment of clinical research quality.
• Consensus achieved via Delphi questionnaire and expert meetings.

Main Results:

• Twelve consensus recommendations for rh-aFGF application in CRWs were formulated.
• Recommendations include guidance on treatment duration, dosage, wound types, and combination therapies.
• Seven strong, four moderate, and one weak recommendation were established for diverse clinical scenarios.

Conclusions:

• rh-aFGF demonstrates significant clinical value in the management of chronic wounds.
• The expert consensus provides a crucial reference for optimizing rh-aFGF therapy.
• This consensus can guide the application of other growth factor drugs with similar mechanisms for CRWs.